CTOs on the Move

Novartis

www.novartis.com

 
Novartis provides healthcare solutions that improve and extend people`s lives. We use science-based innovation to address some of society`s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our company is focused on industry-leading divisions with innovation power and global scale: pharmaceuticals, eye care and generic medicines Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 120,000 associates and its products are available in more than 180 countries around the world.
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.novartis.com
  • 1 Health Plaza
    East Hanover, NJ USA 07936
  • Phone: 862.778.8300

Executives

Name Title Contact Details
Charlene Banard
Global Head of Technical Operations, Cell and Gene Therapy Profile
Andreas Muller
Senior Vice President, Global Head Commercial Information Technology and Chief Information Officer Profile
Jinah Jong
Associate Director, Medical Information Profile
Matthew Standart
Global Head of Cyber Security Operations Center Profile
Erik Johnson
Global Service Delivery Manager - Access and Authentication Profile

Similar Companies

SERVICES Hospital Pharmacy Management and Consulting

SERVICES Hospital Pharmacy Management and Consulting is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

california treats inc

california treats inc is a South El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medaus Pharmacy

Medaus Pharmacy is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inotiv

Inotiv: (bio)analytical, in vivo, toxicology and molecular pathology services for preclinical drug metabolism in drug development.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).